| Trial ID: | L0515 |
| Source ID: | IRCT20171216037911N1
|
| Associated Drug: |
Cichorium Intybus L
|
| Title: |
The effects of aqueous extract of Cichorium Intybus L on non-aloholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
nonalcoholic fatty liver disease. <br>Other diseases of liver;Other diseases of liver
|
| Interventions: |
Intervention 1: Intervention group: They will receive powder of aqueous extracts of 15 g chicory (equivalent to 1 g of extract) prepared by Avigeh Tejarat Sepehr Co. as two 500 mg capsules daily, for 12 weeks. Intervention 2: Control group: The control gr
|
| Outcome Measures: |
Grade of fatty liver. Timepoint: before & 12 weeks after intervention. Method of measurement: liver and bile duct supersonic graphy.;Aspartate aminotransferases. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Waist circumfrence. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: by using of meter.Serum Alanine Aminotransferase. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum ALP. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Weight. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: Mechanical scale.;Serum triglyceride. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Total cholestrol. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum HDL. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum LDL-C. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Fasting plasma glucose. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.
|
| Sponsor/Collaborators: |
Qazvin University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years65 years
|
| Phases: |
Not applicable
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants in the study will randomly assign to two intervention and control groups. A randomized, stratifi
|
| Start Date: |
03/01/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/28280
|
